A safer method of generating pancreatic islet-like cells from human iPS cells

Junior Associate Professor Taro Toyoda and his research group, in collaboration with industrial companies including Orizuru Therapeutics, Inc., conducted a safety assessment of the differentiation inducers used in the preparation of human iPSC-derived pancreatic islet cells (iPIC) from human iPS cells and developed a safer differentiation protocol for generating iPICs based on those new findings. The research results were published in Stem Cell Research & Therapy on January 5, 2023.